Biosyent's total assets for Q3 2025 were C$47.79M, an increase of 9.86% from the previous quarter. TSE:RX total liabilities were C$7.88M for the fiscal quarter, a 33.72% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.